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Ultrasonographic featuresAbstract Aim of the work: To determine sonographic features suggestive of amyloidosis in
hemodialysis patients complaining of shoulder pain, and to study their relations to serum
beta2-microglobulin (b2M).
Patients and methods: Clinical examination, skeletal survey, musculoskeletal ultrasonography of
the shoulder joints, and serum b2M were done for 32 patients with end stage renal disease, who
were regular on hemodialysis.
Results: Serum b2M levels were markedly raised in all patients, and increased with increasing
duration of dialysis (r= 0.91, p< 0.001). Twenty-ﬁve patients had a non homogeneous thickening
of the supraspinatus tendon >7 mm, and thickening of the biceps tendon >4 mm, 30 had synovial
deposits, 27 had subdeltoid bursa effusion, 25 had thickened subacromial bursa, 7 had supraspina-
tus tendon tear, and 17 had bony erosions. Serum b2M levels signiﬁcantly correlated with thickened
supraspinatus tendon (>7 mm) and supraspinatus tendon tear (r= 0.41, p= 0.03 and r= 0.42,
p= 0.01 respectively). Long time on hemodialysis was the signiﬁcant independent determinant
for supraspinatus tendon tear and humeral head erosions (p= 0.001 for each).
Conclusion: Elevated serum b2M levels and sonographic features suggestive of dialysis-related
amyloidosis (DRA) were found in all hemodialyzed patients complaining of shoulder pain either
with or without clinical and/or radiological features suggestive of DRA. So, for diagnosis of
DRA, sonographic features should correspond to the presence of clinically or radiologically evident
b2M amyloid, and we should exclude other causes of non-amyloid changes.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.
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Dialysis-related amyloidosis (DRA) is a disorder caused by tis-
sue deposition of beta2-microglobulin (b2M) as amyloid ﬁbrils
[1]. The tissue deposition of amyloid detected histologically
occurs much earlier than any clinical or radiographic manifes-
tations of the illness. A prospective postmortem study found
joint amyloid deposition in 21% in patients receiving hemodi-
alysis for less than 2 years, 50% at 4–7 years, 90% at
7–13 years, and 100% at more than 13 years [2].
The pathogenesis and pathophysiology of DRA are
probably multifactorial and have been associated with the
duration of renal failure, patient’s current age, patient’s age
at initiation of hemodialysis, duration of hemodialysis,
bioincompatibility of dialysis membranes [3], less residual
renal function, and the coexistence of high-turnover renal
osteodystrophy [4].
Heparin is widely used as an anticoagulant in hemodialysis.
Yamamoto et al. [5] have suggested that heparin could exert a
subtle effect on the development of b2M amyloidosis under
some clinical conditions. Also, Uji et al. [6] have suggested a
possible association of b2M with glycosaminoglycans (GAGs)
containing a sulfate moiety, including heparin, in hemodia-
lyzed patients.
Dialysis-related amyloidosis is characterized by painful stiff
joints, usually ﬁrst involving the shoulder, and less commonly
the hands, wrists, knees, and other large joints. Involvement
tends to be bilateral and symmetrical, and is frequently
associated with the carpal tunnel syndrome (CTS) and
tenosynovitis [7].
As clinical symptoms of DRA are nonspeciﬁc, they may
easily be misinterpreted as other joint diseases [8]. Typical spe-
ciﬁc radiological amyloid bone cysts are a late event. Different
studies observed that capsulosynovial swelling precedes the
development of characteristic bone cysts [9,10]. They are
hypothesizing that amyloid inﬁltration of synovial membrane
and tendons [11–13] might be accessible to ultrasonographic
assessment [14].
Ultrasonography (US) has been suggested as the modality
of choice in evaluating DRA of the shoulder. Thickening of
the supraspinatus tendon greater than 7 mm and thickening
of the long head of the biceps tendon greater than 4 mm, both
in the appropriate clinical setting, have correlated excellently
with DRA of the shoulder [9,15,16].
Biopsy is nearly always required for deﬁnitive diagnosis.
However, because histologic conﬁrmation is not always possi-
ble and increased serum b2M level is not diagnostic, imaging
ﬁndings combined with history and clinical ﬁndings are usually
used for the assessment of musculoskeletal involvement by
DRA [17].
The aims of the studywere to determine sonographic features
suggestive of amyloidosis in hemodialysis patients complaining
of shoulder pain, and to study their relation to serum b2M.
2. Patients and methods
2.1. Study subjects
The study was conducted at the renal unit of Minia University
Hospital, Minia governorate, Egypt. All patients with end
stage renal disease (ESRD), who were regular on hemodialysiswere included. All patients had persistent shoulder pain lasting
for more than 6 weeks. They were 32 patients, 18 males
(56.2%) and 14 females (43.8%). Fifteen healthy age and sex
matched subjects served as controls. Informed consent was
taken from all participants in the study. The study was
approved by the ethics committee of the Faculty of Medicine,
Minia University.
All study patients were undergoing hemodialysis with low-
ﬂux hemodialyzers. All patients were dialyzed 3 times/week.
The duration of each session was 4 h.
Patients having any evidence of autoimmune deﬁciency
syndrome, lymphoproliferative disorders, inﬂammatory disor-
ders like systemic lupus erythematosus, rheumatoid arthritis,
Crohn’s disease, and liver cirrhosis, which lead to rise in
b2M were excluded from the study. Patients with chronic
infections like tuberculosis, chronic osteomyelitis and patients
with primary amyloidosis were also excluded.
2.2. Clinical diagnosis
Patients were examined clinically to show if they completed the
characteristic triad of DRA or not. The triad included ﬂexor
tenosynovitis of the hand with diminished extension of the ﬁn-
gers, signs or symptoms of CTS and shoulder pain with dimin-
ished range of motion [18,19].
2.3. Laboratory investigations
Serum b2M was estimated by ELISA technique (pre hemodial-
ysis) using ORG 5BM beta2-microglobulin kit, the normal
range: 0–3.0 lg/ml [20]. Serum parathyroid hormone (PTH)
was assayed in all patients by the Intact Parathyroid Hormone
ELISA Kit, normal range: 15–55 pg/ml [21].
Blood urea and creatinine were measured in all patients.
The normal plasma concentration of urea was 20–40 mg/dl,
and the normal range of creatinine was 0.6–1.2 mg/dl for male
and 0.5–1.1 for female.
2.4. Imaging
Skeletal survey involving X-rays of the shoulders, pelvis, cervi-
cal spine, lumbar spine, knees and wrists were taken to look
for subchondral bone erosions and cysts, bone fractures,
destructive arthropathy and spondyloarthropathy – character-
istic of amyloidosis [22]. A radiological diagnosis of renal oste-
odystrophy was made if any of the following were present:
subperiosteal resorption, tuft resorption, distal clavicular ero-
sions, Rugger–Jersey spine or other typical bony sclerosis, or
coarse bony trabeculation [23].
All patients underwent musculoskeletal ultrasonography of
the shoulder joints to assess features suggestive of amyloidosis.
Ultrasonograms were obtained and interpreted by one
researcher (F.A., rheumatologist) using conventional grey-
scale ultrasound machine with a 7.5–12 MHz linear trans-
ducer. In the shoulders: tendons were examined, evaluating
changes of their sonographic appearance, alterations of their
margins, modiﬁcations of their thickness and the presence of
peritendinous ﬂuid collection; sonographic signs of bursitis
were searched for [24]. Bony erosion should be speciﬁcally
noted during shoulder sonography as a sign of arthropathy
[16]. The normal supraspinatus tendon thickness was
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thickness from 2.7 to 3.5 mm [25].
Statistical analysis: The statistical analysis was performed
using SPSS 16.0. Descriptive statistics were done by number
and percent as well as mean and SD. ANOVA test was used
to compare the difference between more than two group means
in interval and ordinal variables. Correlations were calculated
using Pearson’s correlation coefﬁcient. A backward/stepwise
multiple linear regression model was used for detection of
independent predictors of ultrasonographic features character-
istic of amyloidosis of the shoulder. The level of statistical sig-
niﬁcance was set at a p level <0.05.
3. Results
3.1. Characteristics of the study population
Demographic data, causes of ESRD and type of heparin used
for studied patients on hemodialysis are shown in Table 1.
The cause of ESRD was not identiﬁed in 11 patients, while
hypertension was the second cause (9 patients). Among all
patients, 18were using low-molecular weight heparin (LMWH),
and 14 were using unfractionated heparin (UFH) in dialysis.
3.2. Clinical and radiological ﬁndings
All patients had shoulder pain with restriction of movement in
5 patients. CTS was found in 18.8%, and ﬂexor tenosynovitis
was found in 15.6%. But only 5 cases (15.6%) with their dial-
ysis durationP10 years completed the clinical triad suggestive
of DRA.
Radiological ﬁndings suggestive of amyloidosis were found
in 9 patients only (28.1%), two of them had the clinical triad.
Typical radiographic changes of renal osteodystrophy were
found in 9 patients (28.1%).
The patients were divided into two groups: group A;
included patients with clinical and/or radiological features
suggestive of DRA (n= 12), and group B; included patients
without clinical and/or radiological features suggestive of
DRA (n= 20).Table 1 Demographic data, causes of end stage renal disease and t
Age (years)
Dialysis duration (years)
Age at dialysis onset (years)
Sex Males
Females
Causes of ESRD Diabetes
Hypertension
Glomerulonephritis
Chronic pyelonephritis
Chronic interstitial nephritis
Renal stone
Hyperuricemia
Unknown
Type of heparin used in dialysis LMWH
UFH
ESRD, end stage renal disease, LMWH, low-molecular weight heparin, U3.3. Laboratory investigations
Predialysis serum b2M levels were markedly raised in both
groups of patients with a signiﬁcant difference in comparison
to their levels in the control group (p< 0.001) as shown in
Table 2, and increased with increasing duration of dialysis
(r= 0.91, p< 0.001) (Fig. 1). There was no signiﬁcant differ-
ence in levels of b2M between patients using LMWH and
those using UFH in dialysis.
Serum parathyroid hormone, blood urea and creatinine lev-
els were raised in both groups of patients with a signiﬁcant dif-
ference in comparison to their levels in the control group
(p< 0.001) (Table 2).3.4. Ultrasonographic ﬁndings
Table 3 summarizes the relevant sonographic features of this
study and shows that the features were more in hemodialyzed
patients than controls. Twenty-ﬁve patients (9 in group A, 16
in group B) had a nonhomogeneous thickening exceeding
7 mm of the supraspinatus tendon (Figs. 2 and 3) and thicken-
ing of the biceps tendon in excess of 4 mm (Fig. 4). Synovial
deposits were detected in 30 patients (11 in group A, 19 in
group B) and appeared as hyperechoic polypoid clusters in
the subdeltoid bursa (Figs. 5 and 6). Subdeltoid bursa effusion
was found in 27 patients (11 in group A, 16 in group B).
Thickened subacromial bursa was found in 25 patients (10
in group A, 15 in group B). Seven patients (4 in group A, 3
in group B) had supraspinatus tendon tear (Figs. 2 and 6).
Bony erosions were found in 17 patients (9 in group A, 8 in
group B) (Fig. 3). There was no signiﬁcant difference in the
previous ﬁndings between patients using LMWH in dialysis
and those using UFH.3.5. Relationship between serum b2M level and features
suggestive of amyloidosis
Serum b2M levels did not correlate with any clinical or
radiological features suggestive of amyloidosis, butype of heparin used for patients on hemodialysis.
Patients on hemodialysis (n= 32) Range (mean ± SD)
19–70 (40.6 ± 13.4)
0.5–23 (6.8 ± 5.1)
11–68.5 (33.8 ± 14.3)
Number (%)
18 (56.2)
14 (43.8)
6 (18.8)
9 (28.1)
2 (6.2)
3 (9.4)
2 (6.2)
2 (6.2)
1 (3.1)
11 (34.4)
18 (56.2)
14 (43.8)
FH, unfractionated heparin.
Figure 1 Correlation between duration of hemodialysis and serum Beta2-microglobulin.
Table 2 Laboratory investigations in the patients on hemodialysis.
Range (mean ± SD) Group A (n= 12) Group B (n= 20) Controls (n= 15) p-Value
b2M (lg/ml) 68.6–97.5 50.3–99.8 1.3–2.4 <0.001*
(84.9 ± 9.1) (75.1 ± 14.8) (1.9 ± 0.3)
PTH (pg/ml) 90–428 66.9–374 11–33 <0.001*
(212.3 ± 117.6) (164.8 ± 96.6) (20.9 ± 7)
Urea (mg/dl) 128–159 (139.3 ± 12.1) 119–178 (141.7 ± 15.4) 20–39 (28.2 ± 5.5) <0.001*
Creatinine (mg/dl) 5.1–7.5 (6.4 ± 0.7) 5.1–8.5 (6.5 ± 0.7) 0.6–1 (0.8 ± 0.1) <0.001*
Test by analysis of variance (ANOVA) for difference between groups. Group A: patients with clinical and/or radiological features suggestive of
dialysis related amyloidosis (DRA), Group B: patients without clinical and/or radiological features suggestive of DRA, b2M= Beta2-
microglobulin, PTH= Parathyroid hormone.
* Signiﬁcant p-value <0.05.
Table 3 Comparison of shoulder ultrasonographic features in the patients on hemodialysis.
Abnormal ultrasonographic ﬁndings N (%) Group A (n= 12) Group B (n= 20) Controls (n= 15)
Thickened supraspinatus tendon (>7 mm) 9 (75) 16 (80) 0
Thickened biceps tendon (>4 mm) 9 (75) 16 (80) 5(33.3)
Polypoid-shaped subdeltoid bursa 11 (91.7) 19 (95) 0
Subdeltoid bursa eﬀusion 11 (91.7) 16 (80) 0
Thickened subacromial bursa 10 (83.3) 15 (75) 6 (40)
Supraspinatus tendon tear 4 (33.3) 3 (15) 0
Humeral head erosions 9 (75) 8 (40) 0
Group A: patients with clinical and/or radiological features suggestive of dialysis related amyloidosis DRA, Group B: patients without clinical
and/or radiological features suggestive of DRA.
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(>7 mm), supraspinatus tendon tear and humeral head
erosions (r= 0.41, p= 0.03 and r= 0.42, p= 0.01 and r=
0.44, p= 0.01 respectively) as shown in Table 4. Other
laboratory investigations (serum PTH, urea, creatinine) did
not correlate with any feature.3.6. Relationship between demographic data, clinical,
radiological, and sonographic features suggestive of amyloidosis
Demographic data did not correlate with any of clinical or
radiological features suggestive of amyloidosis, while duration
of hemodialysis signiﬁcantly correlated with supraspinatus
Figure 4 Longitudinal image of biceps tendon in a 53 year old
male with 8 years dialysis duration showing thickened tendon
>4 mm (arrow).
Figure 5 Transverse examination of subdeltoid bursa in a
48 year old male with 12 years dialysis duration showing hyper-
echoic polypoid clusters in the bursa (star).
Figure 2 Longtudinal image of supraspinatus tendon in a
26 year old female with 17 years dialysis duration showing
thickened tendon with partial tear evident near its insertion
(arrow).
Figure 6 Transverse image of supraspinatus tendon in a 54 year
old male with 9 years dialysis duration showing tear of the tendon
with hyperechoic polypoid clusters in the subdeltoid bursa
(arrow).
Figure 3 Transverse image of supraspinatus tendon in a 45 year
old male patient with 23 years dialysis duration showing nonho-
mogeneous thickening of the tendon (right arrow) and humeral
head erosion (left arrow).
Amyloidosis in hemodialysis patients 205tendon tear and sonographic humeral head erosions (r= 0.46,
p= 0.008 and r= 0.48, p= 0.005 respectively).
There were signiﬁcant correlations between supraspinatus
tendon tear and radiological humeral head cysts and erosions
(r= 0.36, p= 0.03 and r= 0.47, p= 0.004 respectively).
3.7. Predictors of ultrasonographic features suggestive
of amyloidosis
The supposed predictors for ultrasonographic features sugges-
tive of amyloidosis (including; age at onset of dialysis, dialysis
duration, serum b2M level, serum urea and creatinine, pres-
ence of renal osteodystrophy and type of heparin used in dial-
ysis) were analyzed by backward/ stepwise multiple regression
model, and it was found that:
Dialysis duration was the only signiﬁcant independent
determinant for supraspinatus tendon tear (p= 0.001), while
Table 4 Relationship between serum b2M level and ultraso-
nographic features suggestive of amyloidosis.
Ultrasonographic features Serum b2M
r p-Value
Thickened supraspinatus tendon (>7 mm) 0.41 0.03*
Thickened biceps tendon (>4 mm) 0.19 0.3
Polypoid-shaped subdeltoid bursa 0.05 0.7
Subdeltoid bursa eﬀusion 0.14 0.4
Thickened subacromial bursa 0.15 0.4
Supraspinatus tendon tear 0.42 0.01*
Humeral head erosions 0.44 0.01*
* Signiﬁcant p-value <0.05.
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signiﬁcant independent determinants for the humeral head ero-
sions (p= 0.001 for each of which) and therefore retained and
included in the regression equation, while other factors did not
have signiﬁcant contributions in the presence of retained vari-
ables and therefore were excluded.
4. Discussion
Beta2-microglobulin amyloid ﬁbrils primarily accumulate in
the osteoarticular tissues, causing musculoskeletal symptoms,
including polyarthralgia, CTS and bone cysts [26].
In the present study, all patients had shoulder pain with
restriction of movement in 5 cases. CTS was found in
18.8%, and ﬂexor tenosynovitis was found in 15.6%. But only
5 cases (15.6%) complete the clinical triad suggestive of DRA.
Radiological ﬁndings suggestive of amyloidosis were found in
9 patients (28.1%). Radiographic erosions have been confused
with those of hyperparathyroidism [27], since most long-term
dialysis patients also have the secondary form of this.
Serum concentrations of b2M are substantially higher in
patients undergoing hemodialysis than in healthy individuals.
However, serum b2M levels are similar in hemodialysis
patients with and without b2M amyloidosis [28]. In the current
study, serum b2M was found to be 1.9 ± 0.3 mg/L in the con-
trol group which raised to 84.9 ± 9.1 mg/L in patients with
clinical and/or radiological features suggestive of DRA, and
75.1 ± 14.8 in those without (about 60–80 times higher than
that of normal control subjects) as the hemodialysis was
performed with low ﬂux dialysis membranes that were imper-
meable to b2M. Similar high levels were observed by previous
studies [29–32], but Gejyo et al. [33] reported no relation
between onset of DRA and serum level of b2M, while
Dember and Jaber [1] postulated that the onset of DRA may
be after accumulation of b2M with long duration of dialysis
treatment.
Elevated blood levels of b2M are not diagnostic because
virtually all patients with end stage renal disease have elevated
levels and the magnitude of the elevation does not correlate
with the presence of clinical disease [4]. Radiography is not a
sensitive method for the early detection of b2M deposits. In
fact, asymptomatic deposits may antedate symptoms and be
observed early after dialysis onset (within 1 year) [34] or even
before start of dialysis treatment [35].
Among the new imaging methods, ultrasound will probably
be of help in the early detection of soft tissue changes. US ofjoint capsules and tendons has been proposed as a potentially
useful means for diagnosis of DRA [9]. In the present study,
both groups of patients had ultrasonographic features sugges-
tive of amyloidosis in their shoulders. The results of previous
studies [9,15,16,36,37] have been conﬁrmed by our ﬁnding.
Shoulder sonography has been shown to be useful for the diag-
nosis of amyloidosis not only in patients on chronic dialysis
but also in patients with early dialysis.
Thickness of supraspinatus tendon and biceps tendon is
associated with DRA [37]. In 1993, Jadoul and colleagues [9]
conﬁrmed that thickened supraspinatus tendons (greater than
7.8 mm) were markers for DRA. In our study, a nonhomo-
geneous thickening of the supraspinatus tendon >7 mm and
thickened biceps tendon >4 mm were found in 9 patients in
group A and 16 patients in group B. Increased thickness of
the subacromial bursa also was identiﬁed in patients with
DRA [16]. In our study, it was found in 10 patients in group
A and in 15 patients in group B. Amyloid deposition appears
to be the most likely explanation for thickening of tendons and
synovial tissues, although associated inﬂammation also may
contribute [15].
Kiss et al. [17] have reported that, the measured structures
(supraspinatus tendon, biceps tendon and subacromial bursa),
however, may be transiently edematous: tendinitis and synovi-
tis are the main causes of nonamyloid swelling of the supraspi-
natus or biceps tendon. Measurement should, therefore, be
obtained in the absence of clinical symptoms suggestive of
these conditions or, if not possible, repeated 1 month later.
In our study, we cannot exclude causes of nonamyloid swelling
of tendons especially in group B.
Sommer et al. [37] reported hyperechoic polypoid clusters
in the subdeltoid bursa, subdeltoid bursa effusion, and supra-
spinatus tendon tears in dialyzed patients. In our study, polyp-
oid-shaped subdeltoid bursa was found in 11 patients in group
A and 19 patients in group B; and subdeltoid bursa effusion
was found in 11 patients in group A and 16 patients in group
B, while supraspinatus tendon tear was found in 4 patients in
group A patients and 3 patients in group B.
In our patients, serum b2M levels increased with increasing
duration of dialysis (r= 0.91, p< 0.001) which was previ-
ously reported by Fry et al. [38]. No direct relationship
between age and b2M level was seen in the present study which
was similarly reported by Jeloka et al. [29]. Serum b2M levels
did not correlate with any clinical or radiological ﬁndings
suggestive of amyloidosis, but signiﬁcantly correlated with
thickened supraspinatus tendon (>7 mm), supraspinatus ten-
don tear and humeral head erosions (r= 0.41, p= 0.03 and
r= 0.42, p= 0.01 and r= 0.44, p= 0.01 respectively), indi-
cating that these sonographic features had relation to absolute
level of b2M. Long time on hemodialysis was the signiﬁcant
independent determinant for supraspinatus tendon tear and
humeral head erosions (p= 0.001 for each).
Low-molecular weight heparins as well as unfractionated
heparin are used as anticoagulation during hemodialysis ther-
apy. Still commonly used is UFH, followed by LMWH prepa-
rations with distinct advantages [39]. Ariga et al. [40] reported
that LMWH can reverse the process of amyloidosis; inhibit
ﬁbril formation by blocking the formation of b-plated struc-
tures. A possible therapeutic approach using LMWHs to inter-
fere with the interaction between proteoglycans and amyloid
bproteins and to arrest or prevent amyloidogenesis is
suggested.
Amyloidosis in hemodialysis patients 207In the present study, we cannot judge which type of heparin
used in dialysis has a role in the process of amyloidosis, but
mostly UFH was responsible for this as all the patients were
using UFH at the beginning of dialysis then after a period of
time 18 patients were changed to LMWH. Accordingly, we
had no signiﬁcant differences in the levels of b2M and the fre-
quency of ultrasonographic features characteristic of amyloi-
dosis between dialysis patients using LMWH and those using
UFH.
Diagnosis of b2M amyloidosis is suggested primarily by the
characteristic triad: shoulder pain, carpal tunnel syndrome,
and ﬂexor tenosynovitis in the hand. Radiographic ﬁndings
corroborate the diagnosis. Ultrasonography of the shoulder
provides a relatively sensitive and highly speciﬁc adjunct
to the clinical diagnosis especially if it reveals either of
two characteristic changes: rotator cuff thickness greater
than 8 mm or echogenic pads between muscles of the rotator
cuff [41].
This study has some limitations. The number of patients
with clinical and/or radiological features suggestive of DRA
is small, and large series may be needed to estimate sensitivity
and speciﬁcity of ﬁndings. Sonography is an operator depen-
dant technique, and high frequency range of machine may be
needed.
In conclusion, elevated serum b2M levels and sonographic
features suggestive of DRA were found in all hemodialyzed
patients complaining of shoulder pain either with or without
clinical and/or radiological features suggestive of DRA. So,
sonographic features should correspond to the presence of
clinically or radiologically evident b2M amyloid, and we
should exclude other causes of non-amyloid sonographic
changes. Our study determines the relation between serum
b2M and thickened supraspinatus tendon (>7 mm) and supra-
spinatus tendon tear. Longer hemodialysis duration was con-
sidered as a predictor factor for supraspinatus tendon tear
and humeral head erosions. Further studies are needed to con-
ﬁrm the results and to determine the role of heparin in devel-
opment of amyloidosis.
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